Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 30 clinical trials
None
CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC

The objective is to compare the efficacy and safety of CAPOXIRI+BEV therapy versus FOLFOXIRI+BEV therapy as first-line therapy in patients with metastatic colorectal cancer (mCRC).

neutrophil count
leucovorin
irinotecan
metastasis
platelet count
  • 0 views
  • 23 Jan, 2021
  • 1 location
None
FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases

To compare the efficacy of FOLFOXIRI plus Cetuximab and FOLFOXIRI plus Bevacuzumab in the conversion therapy of right-sided colon cancer liver metastases

  • 0 views
  • 15 Apr, 2021
  • 1 location
None
Adjuvant FOLFOXIRI for High-risk Stage III Colon Cancer

A multicenter, open labeled randomized, phase II trial comparing FOLFOXIRI and mFOLFOX6 as adjuvant treatment for high risk stage III (pT4N1/2 or pTanyN2) colon cancer

  • 0 views
  • 12 Jan, 2022
  • 1 location
None
Irinotecan-based Triplet (FOLFOXIRI) as Perioperative Treatment in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma.

In this clinical trial, patients with gastric and gastroesophageal junction adenocarcinoma will be included. Treatment with curative intent will be given with chemotherapy for 4 cycles with fluorouracil, oxaliplatin and irinotecan preoperatively followed by surgery, and then additionally 4 cycles of the same chemotherapy postoperatively. The standard treatment today is …

  • 1 views
  • 19 Mar, 2021
  • 6 locations
None
FOLFOXIRI Compared to FOLFOX in First Line Treatment of Metastatic Colorectal Cancer

The purpose of the study is to evaluate if the exposure to all the three active cytotoxic agents (FOLFOXIRI regimen) is superior in terms of progression-free survival to conventional

neutrophil count
ct scan
metastasis
adenocarcinoma of colon
measurable disease
  • 10 views
  • 08 Nov, 2020
  • 1 location
None
A Trial of Neoadjuvant mFOLFOXIRI Versus CRT in the EMVI Positive LARC

FOLFOXIRI as neoadjuvant chemotherapy alone for EMVI+ LARC in contrast to the efficacy of standard Chemoradiotherapy (CRT).

  • 0 views
  • 30 Mar, 2021
  • 1 location
None
Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels

patients with LDH-CD138 elevated score, the purpose of CLavSyn phase II study is to compare the PFS of one intensified arm (FOLFOXIRI Bevacizumab) to one standard chemotherapy arm, in order to better

metastatic colorectal adenocarcinoma
irinotecan
capecitabine
colorectal adenocarcinoma
folfiri regimen
  • 6 views
  • 03 Aug, 2021
  • 13 locations
None
5FU/LV Irinotecan Temozolomide and Bevacizumab for MGMT Silenced Microsatellite Stable Metastatic Colorectal Cancer.

An upfront-intensified treatment combining all the three active cytotoxic agents in metastatic colorectal cancer (mCRC) including fluoropyrimidines, oxaliplatin, irinotecan (FOLFOXIRI) plus

  • 1 views
  • 01 Mar, 2021
  • 1 location
None
First-line Therapy in Metastatic PDAC

The overarching hypothesis of this trial is that the NAPOLI regimen and alternating cycles of NAPOLI and mFOLFOX6 (seq-NAPOLI-FOLFOX) are superior to the current standard of care gemcitabine/nab-paclitaxel. Furthermore, we propose that the NAPOLI regimen and seq-NAPOLI-FOLFOX display favourable safety profiles and allow for longer first line treatment and higher …

  • 0 views
  • 23 Jan, 2021
  • 1 location
None
Safety Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With Colorectal Cancer

Safety, tolerability and efficacy of regorafenib in combination with FOLFIRINOX in patients with RAS-mutated metastatic colorectal cancer: a dose-escalation, phase I/II trial

thromboplastin
g-csf
metastasis
hysterectomy
aptt
  • 1 views
  • 27 Nov, 2021
  • 4 locations